Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
- First Posted Date
- 2004-06-02
- Last Posted Date
- 2011-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 87
- Registration Number
- NCT00083720
- Locations
- 🇨🇦
ImClone Investigational Site, Toronto, Ontario, Canada
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
- Conditions
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00003669
- Locations
- 🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸Grant/Riverside Methodist Hospitals, Columbus, Ohio, United States
🇺🇸U.S. Oncology, Houston, Texas, United States
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00003670
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
- First Posted Date
- 2004-05-05
- Last Posted Date
- 2010-04-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 25
- Registration Number
- NCT00082212
- Locations
- 🇺🇸
ImClone Investigational Site, Seattle, Washington, United States
Effects of Teriparatide in Postmenopausal Women With Osteoporosis
- Conditions
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2007-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00079924
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States
Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer
- Conditions
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00079872
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sevilla, Spain
A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer
- First Posted Date
- 2004-02-24
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 589
- Registration Number
- NCT00078260
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaziantep, Turkey
Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00006459
- Locations
- 🇺🇸
Office of Alex J.P. Makalinao, Los Angeles, California, United States
🇺🇸Danbury Internal Medicine, Danbury, Connecticut, United States
🇺🇸Comprehensive Cancer Care Specialists of Boca Raton, Boca Raton, Florida, United States
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2003-12-23
- Last Posted Date
- 2008-03-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 511
- Registration Number
- NCT00074828
- Locations
- 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Bydgoszcz, Poland
Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression
- Conditions
- First Posted Date
- 2003-11-21
- Last Posted Date
- 2007-07-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 675
- Registration Number
- NCT00073411
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Cincinnati, Ohio, United States